Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 55, Issue 2, 2017, Pages 473-484

  Darst, Burcu F ^a   Koscik, Rebecca L ^a   Racine, Annie M ^a   Oh, Jennifer M ^a   Krause, Rachel A ^a   Carlsson, Cynthia M ^a,b   Zetterberg, Henrik ^c,d   Blennow, Kaj ^c   Christian, Bradley T ^a   Bendlin, Barbara B ^a   Okonkwo, Ozioma C ^a,b   Hogan, Kirk J ^a   Hermann, Bruce P ^a,b,e   Sager, Mark A ^a   Asthana, Sanjay ^a,b   Johnson, Sterling C ^a,b   Engelman, Corinne D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Alzheimer's disease; amyloid beta; APOE; cerebrospinal fluid; cognitive function; genetic risk scores; genetics; Pittsburgh compound B; polygenic risk scores; WRAP

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; TAU PROTEIN; THIAZOLE DERIVATIVE;

ADULT; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CHOLESTEROL METABOLISM; COGNITION; FEMALE; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROLOGIC DISEASE ASSESSMENT; POLYGENIC RISK SCORE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; COGNITIVE DEFECT; COMPLICATION; DIAGNOSTIC IMAGING; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; METABOLISM; NEUROPSYCHOLOGICAL TEST;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEINS E; COGNITION DISORDERS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS; TAU PROTEINS; THIAZOLES;

EID: 84999098986     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160195     Document Type: Article

References (42)

1. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
3. Mawuenyega KG, SigurdsonW, OvodV, Munsell L, Kasten T, Morris JC,Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
4. Martins IJ, Berger T, Sharman MJ, Verdile G, Fuller SJ, Martins RN (2009) Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem 111, 1275-1308.
5. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM (2011) Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J Immunol 187, 6539-6549.
6. International Genomics of Alzheimer's Disease Consortium (IGAP) (2015) Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimers Dement 11, 658-671.
7. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, Destefano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Hollingworth P, Ramirez A, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Moron FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, European Alzheimer's Disease Initiative (EADI), Genetic and Environmental Risk in Alzheimer's Disease, Alzheimer's Disease Genetic Consortium, Cohorts for Heart and Aging Research in Genomic Epidemiology, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, GuW, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH Jr, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nothen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S,Williams J, Schellenberg GD, Amouyel P (2013) Meta-analysis of 74,046 individuals identifies 11 newsusceptibility loci for Alzheimer's disease. Nat Genet 45, 1452-1458.
8. International Schizophrenia Consortium, Purcell SM,Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752.
9. Wineinger NE, Harper A, Libiger O, Srinivasan SR, Chen W, Berenson GS, Schork NJ (2013) Genomic risk models improve prediction of longitudinal lipid levels in children and young adults. Front Genet 4, 86.
10. Klimentidis YC, Wineinger NE, Vazquez AI, de Los Campos G (2014) Multiple metabolic genetic risk scores and type 2 diabetes risk in three racial/ethnic groups. J Clin Endocrinol Metab 99, E1814-1818.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
12. Sager MA, Hermann B, La Rue A (2005) Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 18, 245-249.
13. La Rue A, Hermann B, Jones JE, Johnson S, Asthana S, Sager MA (2008) Effect of parental family history of Alzheimer's disease on serial position profiles. Alzheimers Dement 4, 285-290.
14. Engelman CD, Koscik RL, Jonaitis EM, Okonkwo OC, Hermann BP, La Rue A, Sager MA (2013) Interaction between two cholesterol metabolism genes influences memory: Findings from theWisconsin Registry for Alzheimer's Prevention. J Alzheimers Dis 36, 749-757.
15. Dowling NM, Hermann B, La Rue A, Sager MA (2010) Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. Neuropsychology 24, 742-756.
16. Darst BF, Koscik RL, Hermann BP, La Rue A, Sager MA, Johnson SC, Engelman CD (2015) Heritability of cognitive traits among siblings with a parental history of Alzheimer's disease. J Alzheimers Dis 45, 1149-1155.
17. Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, Hillmer AT, Wooten DW, Murali D, Barnhart TE, Hall LT, Racine AM, Klunk WE, Mathis CA, Bendlin BB, Gallagher CL, Carlsson CM, Rowley HA, Hermann BP, Dowling NM, Asthana S, Sager MA (2014) Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging 35, 576-584.
18. Sprecher KE, Bendlin BB, Racine AM, Okonkwo OC, Christian BT, Koscik RL, Sager MA, Asthana S, Johnson SC, Benca RM (2015) Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging 36, 2568-2576.
19. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K (2003) Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement Geriatr Cogn Disord 15, 169-176.
20. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213-225.
21. Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J (2015) Amyloid-beta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: Validation of two novel assays. J Alzheimers Dis 43, 183-191.
22. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: A tool set for whole-genome association and population-based linkage analyses.AmJHumGenet 81, 559-575.
23. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29.
24. Xu W, Tan L, Yu JT (2015) The role of PICALM in Alzheimer's disease. Mol Neurobiol 52, 399-413.
25. Carter C (2011) Alzheimer's disease: APP, gamma secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and their relationships with Herpes simplex, C. pneumoniae, other suspect pathogens, and the immune system. Int J Alzheimers Dis 2011, 501862.
26. Guerreiro RJ, Hardy J (2011) Alzheimer's disease genetics: Lessons to improve disease modelling. Biochem Soc Trans 39, 910-916.
27. AlzGene, alzgene.org, Accessed July 15, 2015.
28. Singer JD (1998) Using SAS PROCMIXEDto fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 23, 323-355.
29. Magee L (1990) R 2 measures based onWald and likelihood ratio joint significance tests. Am Stat 44, 250-253.
30. Kramer M (2005) R-squared statistics for mixed models. Proceedings of the 17th annual Kansas State University Conference on Applied Statistics in Agriculture. Boyer JE Jr. (ed.). April 2005, pp. 148-160.
31. Burnham KP, Anderson DR (2002) Information and likelihoood theory: A basis for model selection and inference. In Model Selection and Multimodel Inference, Springer-Verlag, New York, pp. 49-97.
32. Sleegers K, Bettens K, De Roeck A, Van Cauwenberghe C, Cuyvers E,Verheijen J, Struyfs H,Van Dongen J,Vermeulen S, Engelborghs S, Vandenbulcke M, Vandenberghe R, De Deyn PP,Van Broeckhoven C, BELNEU consortium (2015) A 22-single nucleotide polymorphism Alzheimer risk score correlates with family history, onset age, and cerebrospinal fluid Abeta. Alzheimers Dement 11, 1452-1460.
33. Martiskainen H, Helisalmi S, Viswanathan J, Kurki M, Hall A, Herukka SK, Sarajarvi T, Natunen T, Kurkinen KM, Huovinen J, Makinen P, Laitinen M, Koivisto AM, Mattila KM, Lehtimaki T, Remes AM, Leinonen V, Haapasalo A, Soininen H, Hiltunen M (2015) Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: A polygenic risk score approach. J Alzheimers Dis 43, 565-573.
34. Harris SE, Davies G, Luciano M, Payton A, Fox HC, Haggarty P, Ollier W, Horan M, Porteous DJ, Starr JM, Whalley LJ, Pendleton N, Deary IJ (2014) Polygenic risk for Alzheimer's disease is not associated with cognitive ability or cognitive aging in non-demented older people. J Alzheimers Dis 39, 565-574.
35. Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR, Alzheimer's Disease Neuroimaging Initiative (2016) Polygenic risk of Alzheimer disease is associated with early-and late-life processes. Neurology 87, 481-488.
36. Verhaaren BF, Vernooij MW, Koudstaal PJ, Uitterlinden AG, van Duijn CM, Hofman A, Breteler MM, Ikram MA (2013) Alzheimer's disease genes and cognition in the nondemented general population. Biol Psychiatry 73, 429-434.
37. Vivot A, Glymour MM, Tzourio C, Amouyel P, Chene G, Dufouil C (2015) Association of Alzheimer's related genotypes with cognitive decline in multiple domains: Results from the Three-City Dijon study. Mol Psychiatry 20, 1173-1178.
38. Dudbridge F (2013) Power and predictive accuracy of polygenic risk scores. PLoS Genet 9, e1003348.
39. Buchhave P, Minthon L, Zetterberg H,Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of betaamyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
40. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 11, 58-69.
41. Cohen AD, Klunk WE (2014) Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis 72(Pt A), 117-122.
42. Apostolova LG, Hwang KS, Avila D, Elashoff D, Kohannim O, Teng E, Sokolow S, Jack CR, Jagust WJ, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM, Alzheimer's Disease Neuroimaging Initiative (2015) Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology 84, 729-737.